Therefore, we postulate that a pre-treatment targeting NFKB1 could increase the efficacy of TRAIL and MSC-TRAIL-mediated inhibition through CD133+ CSC sensitization in NSCLC. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.